Biologics discovery consulting grounded in experimental reality
I'm a biologic drug discovery scientist with 14 years of R&D experience spanning academic research, diagnostics, manufacturing analytics, and early-stage platform biotech. I've built and scaled molecular biology platforms from scratch — high-throughput screening, automated protein engineering, live-cell functional assays — in environments where budget constraints demanded first-principles thinking at every step.
I recently added computational protein design to my toolkit to solve a specific pain point I encountered repeatedly in previous roles: generating novel protein binders without the headache of patent infringement. I now bring that capability alongside everything else — assay development, screening, protein production, lab operations, and team scaling.
My career has followed the full discovery arc. I started at the bench — cloning, expressing, purifying, characterizing — and progressively built the systems around it: automated screening workflows, functional assay platforms, protein engineering pipelines. Along the way I:
That breadth gives me a practical sense of what scales, what breaks, and where the real bottlenecks are in early discovery.
In previous roles I kept hitting the same wall: we needed protein binders against specific targets, but the available options were either covered by existing IP or required lengthy, expensive campaigns to discover de novo. When generative protein design tools matured to the point where I could build an integrated pipeline around them, I did — and I brought my wet lab judgment with me.
The result is a design platform that doesn't just generate computationally plausible candidates. It filters for developability at every stage, because I understand what happens after the sequences are ordered — expression, purification, screening, and all the ways a promising design can fail in practice.
Minimal Bio is built on reduction to essentials. Whether I'm designing a binder, optimizing an assay, or specifying equipment for a new lab, the method is the same: understand the system at the level of first principles, remove everything that isn't required, and build for reliability and maintainability. The name isn't branding — it's an operating principle.
I document tools, pipelines, and design decisions through tutorials and case studies, with the goal of raising baseline capability across the biotech community.
Whether you need designed binders, screening support, help building a lab, or a full embedded partnership — I'd welcome the conversation.